Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 28;30(1):33-37.
doi: 10.31138/mjr.30.1.33. eCollection 2019 Mar.

Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions

Dimitrios Daoussis  1 , Stamatis-Nick Liossis  1
Affiliations
Review

Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions

Dimitrios Daoussis et al. Mediterr J Rheumatol. .

Abstract

Systemic sclerosis (SSc) is a complicated multisystem disease which is characterized by the highest standardized mortality ratio among all systemic rheumatic diseases with no approved therapies so far. From a pathogenetic point of view it is generally considered that autoimmunity, vasculopathy and fibrosis are the main pathophysiologic processes. In this opinion article/minireview we will discuss current and future options for SSc-related fibrotic manifestations (skin thickening and lung fibrosis). Based on the results of SLS II the best treatment option for skin involvement in SSc is mycophenolate mofetil (MMF). Methotrexate (MTX) is another option which is safe and of low cost but evidence supporting its use is weak. The standard of care for SSc-ILD nowadays is MMF. Patients not responding to MMF could be treated with rituximab (RTX) or cyclophosphamide (CYC) (tocilizumab [TCZ] could be an option as well but only for patients with increased inflammatory markers). Hematopoietic stem cell transplantation (HSCT) could be considered in patients with severe/life-threatening disease who have failed conventional treatment. The most promising therapeutic approach currently been evaluated in phase 3 trials is probably the combination of MMF plus pirfenidone.

Keywords: Systemic sclerosis; fibrotic manifestations; hematopoietic stem cell transplantation; methotrexate; mycophenolate mofetil.

PubMed Disclaimer

References

    1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989–2003. [10.1056/NEJMra0806188] [PMID: ] - DOI - PubMed
    1. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial 2. Arthritis Rheum 2000;43:2445–54. [10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q] [PMID: ] - DOI - PubMed
    1. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009;48 Suppl 3:iii40–i4. [10.1093/rheumatology/kep109] [PMID: ] - DOI - PubMed
    1. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheum 1996;35:364–72. [PMID: ] - PubMed
    1. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66. [10.1056/NEJMoa055120] [PMID: ] - DOI - PubMed

LinkOut - more resources